Table 1.

Adverse events following subcutaneous immunoglobulin (SCIg) administration by pump or rapid push reported at three visits.

Visit number	Rapid push	Pump
Visit 1	n = 72	n = 29
Patients with ≥ 1 adverse event	22 (31%)	9 (31%)
Local reaction	20 (28%)	8 (28%)
Headache	1 (1%)	0
Gastrointestinal (nausea, vomiting, diarrhoea)	1 (1%)	0
Fever	1 (1%)	0
Rash	0	1 (3%)
Other	2 (3%)	0
Visit 2	n = 68	n = 23
Patients with ≥ 1 adverse event	15 (22%)	5 (22%)
Local reaction	15 (22%)	4 (17%)
Headache	0	1 (4%)
Rash	0	1 (4%)
Other	0	1 (4%)
Visit 3	n = 53	n = 21
Patients with ≥ 1 adverse event	8 (15%)	3 (14%)
Local reaction	7 (13%	3 (14%)
Rash	0	1 (5%)